Genomic identification of cryptic susceptibility to penicillins and β-lactamase inhibitors in methicillin-resistant Staphylococcus aureus by Harrison, Ewan M et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genomic identification of cryptic susceptibility to penicillins and
-lactamase inhibitors in methicillin-resistant Staphylococcus
aureus
Citation for published version:
Harrison, EM, Ba, X, Coll, F, Blane, B, Restif, O, Carvell, H, Koser, C, Jamrozy, D, Reuter , S, Lovering, AL,
Gleadall, N, Bellis, K, Uhlemann, A-C, Lowy, FD, Massey, R, Grilo, I, Sobral, R, Larsen, J, Larsen, AR,
Lundberg, C, Parkhill, J, Paterson, G, Holden, MTG, Peacock, S & Holmes, M 2019, 'Genomic identification
of cryptic susceptibility to penicillins and -lactamase inhibitors in methicillin-resistant Staphylococcus
aureus', Nature Microbiology. https://doi.org/10.1038/s41564-019-0471-0
Digital Object Identifier (DOI):
10.1038/s41564-019-0471-0
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Nature Microbiology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 02. Jan. 2020
 1
Genomic identification of cryptic susceptibility to penicillins and β-lactamase 1 
inhibitors in methicillin-resistant Staphylococcus aureus 2 
 3 
Ewan M. Harrison1,2,3¶*, Xiaoliang Ba4¶, Francesc Coll5, Beth Blane2, Olivier Restif4, 4 
Henry Carvell6, Claudio U. Köser7, Dorota Jamrozy1, Sandra Reuter 8 Andrew 5 
Lovering9, Nicholas Gleadhall 2, Katherine L. Bellis2,  Anne-Catrin Uhlemann 6 
10, Franklin D. Lowy 10, Ruth C. Massey 6, Inês R. Grilo11, Rita Sobral11, Jesper 7 
Larsen12, Anders Rhod Larsen12, Carina Vingsbo Lundberg12 Julian Parkhill1, Gavin 8 
K. Paterson13, Matthew T.G. Holden14, Sharon J. Peacock1,2,5§, Mark A. Holmes4§ 9 
Wellcome Sanger Institute, Hinxton, United Kingdom 1 10 
University of Cambridge, Department of Medicine, Cambridge, United Kingdom 2  11 
University of Cambridge, Department of Public Health and Primary Care, Cambridge, 12 
United Kingdom 3  13 
University of Cambridge, Department of Veterinary Medicine, Cambridge, United 14 
Kingdom 4  15 
London School of Hygiene & Tropical Medicine, London, United Kingdom 5 16 
University of Bristol, School of Cellular and Molecular Medicine, Bristol, United 17 
Kingdom 6 18 
University of Cambridge, Department of Genetics, Cambridge, United Kingdom 7  19 
Medical Center – University of Freiburg, Institute for Infection Prevention and 20 
Hospital Epidemiology, Freiburg, Germany 8 21 
University of Birmingham, Institute of Microbiology and Infection and School of 22 
Biosciences, Birmingham, United Kingdom 9 23 
Columbia University, Division of Infectious Diseases, Department of Medicine, New 24 
York, New York, USA.10 25 
UCIBIO@REQUIMTE, Departamento de Ciências da Vida, Faculdade de Ciências e 26 
Tecnologia, Universidade Nova de Lisboa, Lisboa, Portugal 11 27 
Statens Serum Institut, Department of Bacteria, Parasites & Fungi, Copenhagen, 28 
Denmark 12 29 
Royal (Dick) School of Veterinary Studies, University of Edinburgh and The Roslin 30 
Institute, United Kingdom 13 31 
School of Medicine, University of St Andrews, St Andrews, United Kingdom 14 32 
*Corresponding author - Ewan M. Harrison (eh6[at]cam.ac.uk)  33 
 2
 ¶Contributed equally §Co-senior author 34 
 35 
Abstract  36 
Antibiotic resistance in bacterial pathogens threatens the future of modern medicine. 37 
One such resistant pathogen is methicillin-resistant Staphylococcus aureus (MRSA), 38 
which is resistant to nearly all β-lactam antibiotics, limiting treatment options. Here, 39 
we show that a significant proportion of MRSA isolates from different lineages, 40 
including the epidemic USA300 lineage, are susceptible to penicillins when used in 41 
combination with β-lactamase inhibitors such as clavulanic acid. Susceptibility is 42 
mediated by a combination of two different mutations in the mecA promoter region 43 
that lowers mecA-encoded penicillin binding protein 2a (PBP2a) expression, and in 44 
the majority of isolates by either one of two substitutions in PBP2a (E246G or M122I) 45 
that increase the affinity of PBP2a for penicillin in the presence of clavulanic acid. 46 
Treatment of S. aureus infections in wax moth and mouse models demonstrate that 47 
penicillin/β-lactamase inhibitor susceptibility can be exploited as an effective 48 
therapeutic choice for ‘susceptible’ MRSA infection. Finally, we show that isolates 49 
with the PBP2a E246G substitution have a growth advantage in the presence of 50 
penicillin, but the absence of clavulanic acid, which suggests that penicillin/β-51 
lactamase susceptibility is an example of collateral sensitivity (resistance to one 52 
antibiotic increases sensitivity to another). Our findings suggest that widely available 53 
and currently disregarded antibiotics could be effective in a significant proportion of 54 
MRSA infections. 55 
 56 
 57 
 58 
 59 
 60 
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Introduction  61 
The β-lactam family of antibiotics, is one of the most widely used and clinically 62 
important groups of antibiotics 1. Resistance to β-lactam antibiotics in 63 
Staphylococcus aureus is either mediated by the acquisition of the blaZ gene 64 
encoding a β-lactamase, or in methicillin-resistant S. aureus (MRSA) from the 65 
acquisition of an alternative penicillin binding protein 2a (PBP2a) with a low affinity 66 
for β-lactam antibiotics, resulting in resistance to most β-lactams 2. PBP2a is 67 
encoded by mecA or mecC (PBP2a’/c) carried on a mobile genetic element known as 68 
a staphylococcal cassette chromosome mec (SCCmec) 3,4, and is regulated by two 69 
independent regulatory systems (mecI-mecR-mecR2 and blaI-blaR) and multiple 70 
chromosomal genes 5.  71 
 72 
Countering resistance to β-lactams was first achieved by the development of β-73 
lactamase resistant β-lactams such as methicillin 6, and subsequently by the 74 
development of β-lactamase inhibitors 7. Unfortunately, MRSA is resistant to both 75 
methicillin antibiotics and insensitive to β-lactamase inhibitors. However, in the early 76 
1990s, β-lactams and β-lactamase inhibitors were tested against MRSA 8-11, with 77 
success both in vivo and clinically 12.  78 
 79 
Recently, different approaches to restore susceptibility to β-lactams have been 80 
investigated, including using multiple antibiotics to exploit collateral sensitivity 81 
(resistance to one antibiotic increases sensitivity to another) 13-15. We recently 82 
demonstrated that the small subset of MRSA isolates with the mecC gene are 83 
susceptible to penicillins and β-lactamase inhibitors, as the mecC encoded PBP2c 84 
does not mediate resistance to penicillins 16. Here, we demonstrate that 85 
unexpectedly, a significant proportion of all clinical mecA-positive MRSA isolates 86 
from diverse lineages are susceptible to penicillins and β-lactamase inhibitors. These 87 
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findings could provide the basis of new treatment options for susceptible MRSA 88 
infections using already licenced antibiotics.  89 
 90 
Results  91 
Penicillin/β-lactamase inhibitor-susceptible MRSA 92 
As part of an earlier study 16, we identified an mecA-positive MRSA isolate that 93 
exhibited increased susceptibility to penicillin in the presence of clavulanic acid (a β-94 
lactamase inhibitor) (Fig 1a). We screened a selection of whole genome sequenced 95 
(WGS) MRSA isolates (n = 110) from different clinically relevant clonal lineages for 96 
the same increase in susceptibility (≥10 mm increase in the zone of inhibition in the 97 
presence of 15 μg/ml clavulanic acid, compared to penicillin alone). Fifty-five (50.0%) 98 
isolates from different lineages were susceptible to penicillin-clavulanic acid 99 
(Supplementary Table 1). We determined the minimum inhibitory concentration (MIC) 100 
for penicillin for a subset of isolates, which showed that the MIC was reduced below 101 
the European Committee on Antimicrobial Susceptibility Testing (EUCAST) / Clinical 102 
and Laboratory Standards Institute (CLSI) breakpoint (≤0.125 μg/ml) 17,18  in ten of 103 
the fourteen susceptible isolates, and none of the ten resistant isolates (Fig. 1b). Two 104 
other β-lactam inhibitors, sulbactam and tazobactam also increased susceptibility to 105 
penicillin (Supplementary Fig. 1), suggesting that the effect of clavulanic acid was 106 
due to inhibition of the staphylococcal β-lactamase. Next, we evaluated if the 107 
increase in susceptibility was penicillin-specific by screening isolates against different 108 
β-lactam antibiotics in the presence of clavulanic acid (Fig. 1c and d). This revealed 109 
that the penicillin-clavulanic acid susceptible isolates showed the greatest increase in 110 
susceptibility to penicillins (benzyl- and aminopenicillins), (Fig. 1d) and were broadly 111 
more susceptible to cephalosporins (except ceftaroline) and carbapenems than the 112 
resistant isolates (Fig 1c). In contrast, the presence of clavulanic acid produced only 113 
minor increases in susceptibility in the resistant isolates (Fig 1c).  114 
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Substitutions in PBP2a mediate increased penicillin susceptibility 115 
Benzyl- and aminopenicillins bind reasonably well to PBP2a in comparison to the 116 
isoxazolyl penicillins (oxacillin) and cephalosporins 19. As amino acid substitutions in 117 
PBP2a mediate resistance to fifth-generation cephalosporins 20, in the absence β-118 
lactamase activity, we hypothesised that inversely, increased susceptibility to 119 
penicillins might be mediated by PBP2a substitutions. We examined the PBP2a 120 
amino acid sequences of the 110 isolates (Supplementary Table 1). This revealed 121 
that 80.0% (44/55) of the penicillin-clavulanic acid susceptible isolates had either a 122 
E246G (PBP2a246G) (n=37) or a M122I (PBP2a122I) (n=7) substitution in the allosteric 123 
domain of PBP2a 21. By contrast, only 29.1% (16/55) of the resistant isolates had the 124 
PBP2a246G substitution. Phylogenetic analysis of PBP2a indicated that 246E is 125 
present in the S. aureus COL genome (M122I was absent), an early MRSA strain 126 
isolated in the 1960s, with origins in the 1940s 22,23, suggesting this might be the 127 
ancestral or ‘wildtype’ form (Supplementary Fig. 2). 128 
 129 
Next, we tested the effect of the PBP2a substitutions experimentally. We deleted 130 
mecA (PBP2a) in isolates from two S. aureus lineages: ST398 (EC139 24) and 131 
USA300/ST8 (BCVA289 25) (both PBP2a246G and blaZ positive) and introduced 132 
plasmid-borne copies of three mecA alleles: the putatively resistant ‘wildtype’ 133 
mecA246E and the two alleles associated with susceptibility: mecA122I and mecA246G. 134 
All the complemented strains were resistant to penicillin alone (MICs >20μg/ml - 135 
breakpoint >0.125μg/ml) (Fig. 2a). For penicillin-clavulanic acid, the mecA246E strains 136 
were resistant with MICs of 1μg/ml (Fig. 2a). While the strains with mecA246G were 137 
susceptible, with MICs of 0.125μg/ml. Similarly strains with mecA122I had MICs of 138 
0.125 and 0.25μg/ml for USA300 and ST398 backgrounds, respectively. No 139 
difference in susceptibility was seen for cefoxitin (a cephalosporin), confirming that 140 
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the effect of the substitutions was limited to penicillin susceptibility (Supplementary 141 
Table 2).  142 
 143 
A combination of mecA promoter mutations and PBP2a substitutions mediate 144 
susceptibility 145 
We reasoned that the PBP2a substitutions might cause an increase in the affinity of 146 
PBP2a for penicillin. We tested PBP2a246E, PBP2a246G and PBP2a122I in a bocillin 147 
competition assay to determine their relative binding affinities for penicillin (Fig 2b). 148 
This identified that all three variants had a similar affinity for penicillin, with 50% 149 
inhibitory concentrations (IC50) of 10.63 µg/ml (standard error of the mean ± 0.53) for 150 
PBP2a246G and 12.11(± 1.07) for PBP2a122I and 9.06 (± 2.70) for PBP2a246E (Fig 2b). 151 
As susceptibility testing had been carried out in the presence of clavulanic acid, we 152 
repeated the bocillin binding assays with 15 µg/ml clavulanic acid. In the presence of 153 
clavulanic acid, the wildtype PBP2a246E had a two-fold higher IC50 of 32.07 (± 8.38) 154 
compared to that PBP2a246G 16.22 ± 3.19) and PBP2a122I (11.73 ± 4.50), which were 155 
virtually unaffected (Fig 2c). 156 
 157 
To confirm the consistency of association between the two PBP2a substitutions and 158 
phenotypic susceptibility, we determined the penicillin and penicillin-clavulanic acid 159 
MICs for 274 WGS isolates from a range of S. aureus lineages (Supplementary 160 
Table 3). We then combined the data with the original 24 isolates with MIC data (Fig. 161 
1b) and plotted the frequency distributions of the penicillin and penicillin-clavulanic 162 
acid MICs (Fig. 2d and e). In the absence of a clinical breakpoint for penicillin-163 
clavulanic acid we determined a tentative epidemiological (wildtype) cut-off (ECOFF) 164 
using a statistical method based on mixture models 26,27. This supported setting the 165 
ECOFF between 2.0 and 3.0 µg/ml (2.449, rounded down to 2.0 µg/ml) for penicillin 166 
in the presence of 15 µg/ml clavulanic acid (Fig 2d). The same method supported an 167 
ECOFF between 0.19 and 0.25 µg/ml (0.21, rounded down to 0.19 µg/ml) for 168 
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penicillin alone, which is within one doubling dilution of the EUCAST clinical 169 
breakpoint (Fig 2e)18. Using the ECOFF of ≤2.0 μg/ml as the cut-off, 213 (71.5%) 170 
isolates were classified as susceptible to penicillin-clavulanic acid, of which only 176 171 
(82.6%) had either a 246G or 122I substitution. This indicated that 37 (17.4%) 172 
isolates were susceptible despite having no PBP2a substitution. Conversely, only 37 173 
(43.5%) of the resistant isolates (MIC >2 µg/ml) had a 246G substitution. 174 
 175 
Incomplete congruence between PBP2a substitutions and penicillin-clavulanic acid 176 
susceptibility led us to search for further mutations involved in susceptibility. We 177 
hypothesised that higher levels of PBP2a expression might overcome the effect of 178 
the PBP2a substitutions. We screened the same 298 isolates for mutations in the 179 
mecA promoter region, this identified two mutations that correlated with susceptibility.  180 
The first mutation was a G to T transversion in the mecA ribosomal binding site 181 
(RBS), seven nucleotides upstream of mecA start codon (Fig 3a). Isolates with the 182 
mecA[-7]:T allele had a median penicillin-clavulanic acid MIC of 0.125 μg/ml (range 183 
<0.016 – 6) compared to a median of 8 μg/ml (range: 0.023 – 96) for isolates with the 184 
‘wildtype’ mecA[-7]:G. Previous work has demonstrated that despite being in the 185 
RBS, the T allele results in lower mecA transcript and PBP2a expression levels 28. 186 
We compared relative levels of mecA expression by reverse transcription quantitative 187 
polymerase chain reaction (RT-qPCR) in isolates from phylogenetically separate 188 
lineages with the mecA[-7]:G (n=7) allele to isolates with the mecA[-7]:T allele (n=6) 189 
(Fig 3b). Isolates with the T allele had a statistically significantly lower relative 190 
expression (mean relative expression: 3.24) than isolates with the G allele (mean: 191 
7.00) (P=0.0048) (Fig 3b). The second mutation was a C to T transition in the mecA -192 
10 box, 33 nucleotides upstream of the mecA start codon (mecA[-33]:T) (Fig 3a). 193 
Isolates with this mutation had a median penicillin-clavulanic acid MIC of 0.047μg/ml 194 
(range: <0.016 to 0.125). The C to T transition causes the generation of a perfect 195 
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palindrome within the MecI-BlaI binding site, which lowers mecA transcript and 196 
PBP2a expression levels 28,29. Three isolates from distinct lineages with the mecA[-197 
33]:T mutation had a mean relative expression rate of 0.27, suggesting the C to T 198 
transition results in very low levels of mecA expression in the tested isolates (Fig 3b).   199 
 200 
When considering the two promoter mutations (mecA[-7]:G-T and mecA[-33]:C-T) 201 
together with the two PBP2a substitutions (PBP2a246G and PBP2a122I) (Fig 3a) we 202 
identified six genotypes. These were used to annotate the MIC distributions for 203 
penicillin and penicillin-clavulanic acid (Fig 3c and d). For penicillin-clavulanic acid, 204 
the genotypes split clearly into the bimodal distribution (Fig 3c). The majority of 205 
isolates with mecA[-7]:G (henceforth: Resistant 1) and mecA[-7]:G | E246G 206 
(Resistant 2) genotypes were found in the modal peak to the right with MICs above 207 
the ECOFF of ≥2 μg/ml (Fig 3c). The majority of isolates with the other four 208 
genotypes: mecA[-7]:G-T (henceforth: Susceptible 1), mecA[-7]:G-T | E246G 209 
(Susceptible 2), mecA[-33]:C-T | mecA[-7]:G | E246G (Susceptible 3) and mecA[-210 
7]:G | M122I (Susceptible 4) were located in the modal peak to the left with MICs 211 
below the ECOFF (≤2.0 µg.ml). Isolates with susceptible genotypes had lower 212 
penicillin MICs in the absence of clavulanic acid than those with resistant genotypes 213 
(Fig 3c and d). The use of the six genotypes to predict susceptibility using the 214 
ECOFF as breakpoint was accurate in 94.6% (282/298) of isolates, with a 0.34% 215 
(1/298) very major error (VME) rate (defined as isolates that were phenotypically 216 
resistant but genotypically predicted to be susceptible) and a 5.0% (15/298) major 217 
error (ME) rate (phenotypically susceptible, genotypically predicted resistant).  218 
 219 
Finally, we investigated if the presence of the six different types of class A 220 
staphylococcal ß-lactamases (types A-F), or blaZ expression levels might affect 221 
penicillin-clavulanic acid susceptibility 16. There was no association between the ß-222 
lactamase type and susceptibility that wasn’t better explained by the six genotypes 223 
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(Supplementary Table 3 and Fig. 3a). Nor was there any significant association (P= 224 
0.43) between blaZ expression and susceptibility in twenty isolates (11 susceptible, 9 225 
resistant) as measured by RT-qPCR (Supplementary Fig. 3b).  226 
 227 
Clinical prevalence and epidemiology 228 
We sought to quantify the frequency of penicillin-clavulanic acid susceptibility in 229 
clinical MRSA isolates. We tested a collection of 270 S. aureus isolates (MRSA, n = 230 
218; MSSA isolates, n = 52) collected by the Danish Staphylococcus Reference 231 
Laboratory as part of bacteraemia surveillance 30 (Supplementary Table 4). Isolates 232 
were classified as resistant or susceptible based on the ECOFF of ≤2.0 μg/ml 233 
penicillin in the presence of 15 μg/ml of clavulanic acid. All MSSA isolates, and 234 
84.9% (185/218) of the MRSA isolates had an MIC below the ECOFF. The MRSA 235 
isolates were from a variety of lineages as inferred from spa-typing including clonal 236 
complex (CC)1, CC5, CC8, CC30 and CC80. We then screened 2282 WGS MRSA 237 
isolates from Cambridge, UK for the six genotypes (Fig. 4a) 31. None of the isolates in 238 
this collection had the Susceptible 4 genotype. Overall, 25.0% of isolates had one of 239 
the three remaining putative susceptible genotypes (Fig 4a). The dominant UK 240 
MRSA sequence type is ST22 (EMRSA-15), if the CC22 isolates (70.4% of isolates) 241 
were excluded then 82.8% (n=610) had one of three susceptible genotypes (Fig. 4a). 242 
Lineages with a high abundance of susceptible genotypes included CC1, CC5, CC8, 243 
CC30 and CC59 (Fig. 4a). Importantly, 56 of the CC8 isolates (from 24 patients) 244 
were USA300 which is the dominant clonal lineage in the United States (USA) 32. All 245 
56 USA300 isolates had the Susceptible 2 genotype and a penicillin-clavulanic acid 246 
MIC below the ECOFF (Supplementary Table 3). We performed a phylogenetic 247 
analysis of 580 CC8 isolates, including 485 USA300 isolates (457 MRSA, 28 MSSA) 248 
from across the USA 33,34. All 457 of the USA300 MRSA isolates had the Susceptible 249 
2 (mecA[-7]:G-T | E246G) genotype carried on a SCCmec type IVa (n=455) or IVb 250 
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element (n=1) (one isolate was non-SCCmec typeable), suggesting that the majority 251 
of the USA300 population is susceptible to penicillin-clavulanic acid (Fig 4b). We then 252 
screened 23 USA300 isolates, distributed across the phylogeny (isolated in New 253 
York 34) for penicillin-clavulanic acid susceptibility (Fig. 4b). All had an MIC below the 254 
ECOFF (<2 µg/ml) (Supplementary Table 5).  255 
 256 
Heterogeneity of susceptible populations 257 
β-lactams resistance in most MRSA is heterogenous, meaning that while most cells 258 
in a population have low MICs, a fraction (10-4–10-8) can survive at much higher MICs 259 
35. We tested representative isolates for all six penicillin-clavulanic acid susceptibility 260 
genotypes in a population analysis for their susceptibility profile to penicillin-261 
clavulanic acid. Isolates representing the four susceptible genotypes all displayed 262 
heterogenous resistance to penicillin-clavulanic acid (Fig 5a). CFUs were drastically 263 
reduced at low concentrations of penicillin (0.12 to 1 µg/ml) and susceptible isolates 264 
had a median population MIC of 12 µg/ml (range 0.48 to 32) (Fig 5a). Notably, for 265 
four isolates from three different genotypes (Susceptible 1, 3, and 4) the entire 266 
population was completely inhibited by 4 µg/ml. The remainder of susceptible 267 
isolates had ‘highly resistant cells’ (cells capable of growing in concentrations greater 268 
than the ECOFF of ≤2 µg/ml) present at a frequency of 10-5–10-8. In contrast, 269 
resistant isolates displayed homogenous resistance to penicillin-clavulanic acid (Fig 270 
5a). CFUs of resistant isolates were unaffected at the lower penicillin concentration 271 
range (0.12 to 1 µg/ml) and had a higher median population MIC of 64 µg/ml (range 272 
64 to 128), greater than the susceptible isolates (Fig. 5a). Highly resistant cells (MIC 273 
≥4 µg/ml) were also present at higher frequencies (1–10-4) than susceptible isolates. 274 
 275 
Pencillin-clavulanic acid is effective for MRSA treatment in vivo 276 
We next sought to demonstrate efficacy in physiologically relevant infection models in 277 
which highly resistant cells would be present. First, we used a wax moth larvae 278 
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model of infection, larvae were infected with four different MRSA isolates, two with a 279 
resistant genotype (both ST22: Resistant 1) and two with a susceptible genotype 280 
(ST398 and ST8 (USA300): Susceptible 2). Treatment at approximate human 281 
dosages was with penicillin, penicillin-clavulanic acid, amoxicillin, amoxicillin-282 
clavulanic acid, vancomycin or PBS (vehicle). Only vancomycin offered any 283 
improvement in survival for the two resistant isolates (Fig 5b and c). In contrast, for 284 
the two susceptible isolates both penicillin-clavulanic acid and amoxicillin-clavulanic 285 
acid increased survival in comparison to penicillin or amoxicillin alone, increasing the 286 
median survival times by 40 hours (Fig 5d and e). Given that amoxicillin-clavulanic 287 
acid is clinically available, we further tested its efficacy in a more physiologically 288 
relevant, higher infective dose (1 x 107 CFU) murine thigh infection model, with 289 
approximate human dosages using a USA300 strain (strain: MRSA 43484 36 290 
(Susceptible 2, penicillin-clavulanic acid MIC: 0.19 μg/ml, population analysis: 291 
Supplementary Fig. 4), USA300 phylogeny: Fig. 4b). Treatment with amoxicillin alone 292 
in a dose range of 10 – 100 mg/kg did not reduce the bacterial loads compared to 293 
vehicle treatment, whereas 100 mg/kg amoxicillin in combination with 20 mg/kg 294 
clavulanic acid significantly reduced the bacterial loads to a similar level as 40 mg/kg 295 
vancomycin (Dunnett's multiple comparisons test, p<0.0001) (Fig. 5f). Demonstrating 296 
the efficacy of amoxicillin-clavulanic acid as a treatment in a high dose infection 297 
model. 298 
 299 
PBP2a substitutions provide a growth advantage in the presence of penicillin 300 
As the acquisition of mecA (PBP2a) in a SCCmec element can exhibit significant 301 
fitness costs 37, and affect toxicity 38 and biofilm formation 39, we hypothesised that 302 
the PBP2a substitutions might confer a fitness advantage.  We found no significant 303 
difference in biofilm formation or toxicity to human monocytic cells between any of 304 
the three PBP2a variants in two strain backgrounds (Supplementary Fig. 6). We then 305 
investigated the effect of the PBP2a substitutions on general fitness in three lineages 306 
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(ST22, USA300/ST8) and ST398) assayed by growth in a minimal medium, and in 307 
the presence of penicillin. In minimal medium, there were only minor differences (Fig 308 
6a, c, e), with the USA300 strain (BCV289) complemented with mecA246G growing 309 
marginally better in early exponential phase than mecA246E or mecA122I (Fig. 6a). In 310 
the ST22 (A75) background the mecA246E strain grew slower during exponential 311 
growth than the other backgrounds (Fig 6e). In the presence of penicillin, in all three 312 
strain backgrounds the isolates complemented with mecA246G grew better than the 313 
other two variants (Fig 6b, d and f). This was most pronounced in the ST398 314 
background (EC139), in which mecA246G  strain grew considerably better in 315 
exponential phase, reached a higher optical density and grew with a reduced 316 
doubling time (dt) of 5.33 hours (95% confidence intervals (CI): 5.28 to 5.38) 317 
compared to either mecA246E (dt: 6.65, 95% CI: 6.62 to 6.69) or mecA122I (dt: 6.92, 318 
95% CI: 6.89 to 6.96) (Fig 6d). This demonstrated that complementation with 319 
mecA246G provided a growth advantage in the presence of penicillin, but the 320 
magnitude of this effect is influenced by strain background.  321 
 322 
Discussion 323 
We show that a significant proportion of clinical MRSA isolates are susceptible to a 324 
combination of penicillins and a β-lactamase inhibitor. Susceptibility is due to one of 325 
two different mutations in the mecA promoter region that both lower mecA (PBP2a) 326 
expression, and in the majority of isolates, by an additional substitution in PBP2a 327 
(E246G or M122I) that increases the affinity of PBP2a for penicillin in the presence of 328 
clavulanic acid. It is not clear how clavulanic acid causes the increased binding 329 
affinity of penicillin for PBP2a, as clavulanic acid binds to PBP2a poorly 19. Modelling 330 
of PBP2a shows that position 246 is located near the allosteric site but does not 331 
indicate any clear mechanism for the increased affinity for penicillin (Supplementary 332 
Fig.7 and Supplementary Discussion). In some isolates, a RBS mutation alone 333 
appeared to be sufficient to mediate susceptibility, although given the complexity of 334 
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the regulation of β-lactam resistance in MRSA other genes might be involved 5. 335 
Crucially, the PBP2a 246G substitution provides a fitness benefit for growth in 336 
presence of penicillin, suggesting that susceptibility to penicillin and β-lactamase 337 
inhibitors is a likely a case of collateral sensitivity 40, which evolved due to selective 338 
pressure for maintaining the balance between fitness and resistance.  339 
 340 
In our susceptibility assays we used Iso-Sensitest media (ISA) rather than Müller-341 
Hinton agar (MHA) as currently recommended by CLSI  and EUCAST 18,19, because 342 
ISA was the recommended media for penicillin by the British Society for Antimicrobial 343 
Chemotherapy (BSAC) at the beginning of the study 41. Comparison between 344 
susceptibility to penicillin-clavulanic acid on ISA and MHA revealed that a number of 345 
isolates that were susceptible on ISA remained resistant on MHA (Supplementary 346 
table 5), including isolates that responded to treatment in vivo (Fig 5b-e). This 347 
suggests that MHA is not the optimum media for the detection of susceptibility of 348 
penicillins and β-lactamase inhibitors, which is supported by a recent study which 349 
revealed that MHA failed to detect susceptibility to multiple antibiotic classes that 350 
were effective in vivo 42. Our data also highlights the risk of using a single antibiotic 351 
(e.g. cefoxitin for MRSA) to determine resistance to an entire antibiotic class, 352 
potentially missing unexpected susceptibilities.  353 
 354 
Both in vitro and in vivo, penicillins and clavulanic acid were efficacious at 355 
physiologically achievable concentrations 43. In the absence of a clinical breakpoint, 356 
pharmacokinetic-pharmacodynamic (PK-PD) breakpoints can be used to infer 357 
susceptibility 44. The tentative ECOFF wildtype cut-off of ≤2.0 µg/ml penicillin in the 358 
presence of 15 μg/ml of clavulanic acid, lies in the intermediate susceptibility 359 
category (susceptible ≤0.25 µg/ml, resistant >2 µg/ml) of the EUCAST PK-PD 360 
breakpoint 18. Large numbers of isolates had much lower MICs, and had amoxicillin-361 
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clavulanic acid zone diameters greater than the breakpoint for other pathogenic 362 
species (Supplementary Table 1, 3 and 4) 18. Previous studies have reported the 363 
successful use of penicillins and β-lactamase inhibitors for the treatment of MRSA in 364 
rabbits and rats, and for human infections 11,45-47. This work, provides a mechanistic 365 
explanation for efficacy in these studies, although there have been previous 366 
conflicting reports 9. While it is unlikely that penicillins and β-lactamase inhibitor 367 
combinations would be used as a monotherapy, they would be attractive additional 368 
therapeutic option for hard-to-treat infections such as multidrug-resistant MRSA 48, 369 
particularly as β-lactams synergise with vancomycin and daptomycin 49,50. PK/PD 370 
modelling studies, including an assessment of highly resistant cells during treatment 371 
is now needed to determine the optimum dosing strategy required for sustained 372 
efficacy before appropriate clinical trial could be conducted.  373 
 374 
Our findings demonstrate that cryptic susceptibilities to already licensed and 375 
inexpensive antibiotics may emerge within constantly evolving bacterial populations, 376 
which then can be exploited for the treatment of antibiotic resistant pathogens.  377 
 378 
 379 
 380 
 381 
 382 
 383 
 384 
 385 
 386 
 387 
 388 
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Material and methods 389 
Media and culture conditions  390 
Bacterial strains and plasmids used in this study are described in Supplementary 391 
Table 5 and 6. For routine culture, Escherichia coli (E. coli) was grown in Lysogeny 392 
broth (LB) or on LB-agar (Oxoid, UK) at 37°C. S. aureus was grown on tryptone soy 393 
agar (TSA), Columbia blood agar or in tryptone soy broth (TSB) (Oxoid, UK) at 28°C 394 
or 37°C accordingly. E. coli and S. aureus media were supplemented with 10 µg/ml 395 
chloramphenicol (Cm10) as appropriate. For growth curve studies, S. aureus strains 396 
were grown in SSM9PR minimal medium (1 × M9 salts, 2 mM MgSO4, 0.1 mM CaCl2, 397 
1% glucose, 1% casaminoacids, 1 mM Thiamine-HCl and 0.05 mM nicotinamide) at 398 
37°C 51.  399 
 400 
Isolate selection 401 
For the 110 sequenced isolates in Supplementary Table 1, isolates were selected 402 
from sequenced isolates in our laboratory collections to provide a broad as possible 403 
selection of isolates as possible from different clinically relevant lineages (Multilocus 404 
sequence type (ST)1, 5, 8 22, 36, 45, 80, 88, 239, 398), with an obvious bias towards 405 
lineages that dominate in the UK (e.g. 40 isolates from ST22, which is the dominant 406 
lineage in the UK). For the additional 274 isolates that were combined with 24 of the 407 
original isolates with MIC data (from the previous 110), we again tried to select 408 
isolates from our laboratory collections that broadly covered a selection of clinically 409 
relevant MRSA lineages including clonal complex (CC) 1, 5, 8 (including 56 UK 410 
USA300 isolates), 22, 30 , 45 , 59, 72, 80 , 97, 239, and 398 - amongst others). For 411 
lineages with multiple isolates (CC1, n=25, CC5, n=29, CC22, n=91, CC59, n=18, 412 
CC45, n=15, CC30, n=20) we used previously generated whole genome phylogenies 413 
31 to select isolates broadly across the phylogeny, as well as selecting isolates from 414 
the same clades.  415 
 416 
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Antimicrobial susceptibility testing  417 
Inocula were prepared by the growth method. At least four morphologically similar 418 
colonies were touched with a sterile loop and transferred into Iso-Sensitest broth 419 
(Oxoid, UK). Inoculated broth was incubated at 37°C with 200 rpm shaking until the 420 
visible turbidity reached 0.5 McFarland standard. For disk diffusion and Etest method 421 
testing, the 0.5 McFarland standard broth was diluted 1:10 in distilled water before 422 
spreading onto agar plates. For Microbroth dilution for minimum inhibitory 423 
concentrations (MIC), the broth was diluted 1:100 in Iso-Sensitest broth for 424 
inoculation.  425 
 426 
Disk diffusion susceptibility testing was carried out according to BSAC criteria (BSAC 427 
Methods for Antimicrobial Susceptibility Testing, version 14, January 2015). 428 
Temocillin disks were purchased from MAST group, UK. All other antibiotic disks 429 
were purchased from Oxoid, UK. For the clavulanic acid assay, 15 µg/ml clavulanic 430 
acid (Sigma-Aldrich, UK) was added to Iso-Sensitest agar (ISA) or Müller-Hinton agar 431 
(MHA) (Oxoid, UK), as appropriate. After applying the antibiotic disks, all plates were 432 
incubated at 35°C for 20 hours before inhibition zones were measured. Oxacillin disk 433 
diffusion was also performed on MHA with 2% NaCl at 30°C for 24 hours. For disk 434 
testing with clavulanic acid, susceptibility was defined as ≥10 mm increase of the 435 
zone of inhibition in the presence of 15μg/ml clavulanic acid. For mecA 436 
complemented strains, ISA was supplemented with 200 ng/ml anhydrotetracycline 437 
(Atc) (Sigma-Aldrich, UK) to induce expression of mecA from pXB01, a modified 438 
tetracycline-inducible expression vector pRMC2 16. Microbroth dilution for minimum 439 
inhibitory concentrations (MIC) was performed according to BSAC guidelines 52. The 440 
antibiotic ranges were prepared in Iso-Sensitest broth a step higher than the final 441 
concentrations of 0.015-128 µg/ml for penicillin and 1-32 µg/ml for cefoxitin. A 96 well 442 
cell culture plate (Greiner Bio-One, CELLSTAR®) was loaded with appropriate 443 
antibiotic dilutions. For each test isolate, 75 µl of each antibiotic dilution were added 444 
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to a row of wells and 75 µl diluted test isolate culture was added into the wells. Each 445 
isolate was tested in triplicate. The 96 well plate was then placed in a plastic bag to 446 
minimize evaporation and was incubated at 35°C for 20 hours.  Penicillin and 447 
cefoxitin Etest antimicrobial susceptibility testing on selected MRSA isolates was 448 
performed according to manufacturer’s guidance. Medium used for Etest was ISA 449 
with or without 15 µg/ml clavulanic acid. Etest strips were purchased from bioMérieux 450 
UK Ltd. 451 
 452 
Construction of S. aureus gene deletion and complementation mutants 453 
mecA deletion mutants in mecA-MRSA strains (Supplementary Table 7) were 454 
generated by allelic exchange with the temperature-sensitive vector pIMAY, as 455 
described previously 53. Primers used for mecA deletion are listed in Supplementary 456 
Table 8. Upstream sequence (AB) and downstream sequence (CD) of the S. aureus 457 
gene to be deleted were amplified with primers A/B or C/D using KOD Hot Start DNA 458 
Polymerase (Merck, UK). PCR products AB and CD were used as templates to 459 
obtain deletion construct AD with primers A/D in a splicing overlap extension (SOE) 460 
PCR. Product AD was digested with restriction enzymes KpnI and SacI and ligated to 461 
pIMAY digested with the same enzymes. The resulting plasmids were designated 462 
pIMAYΔmecA. The plasmids were transformed into E. coli DC10B (a dcm deletion 463 
mutant of DH10B), allowing the plasmid to be directly transferred into S. aureus 464 
strains 53. Plasmid DNA extracted from DC10B was then electroporated into recipient 465 
strains to create knockout mutants.  466 
 467 
For complement expression of mecA, the genes were cloned into expression plasmid 468 
pXB01, a derivate of tetracycline-inducible expression vector pRMC2 with the blaZ 469 
gene deleted 54. The mecA gene variants including the ribosome binding site were 470 
amplified from genomic DNA with primers: mecA-F-KpnI / mecA-R-SacI. PCR 471 
products were digested with KpnI and SacI and ligated with the pXB01 vector 472 
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cleaved with the same enzymes, generating plasmids pmecA246E, pmecA246G, and 473 
pmecA122I.The plasmids were transformed into E. coli DC10B, and plasmid DNA then 474 
extracted and electroporated into mecA-deletion strains for complementation with 475 
expression induced with 200 ng/ml Atc.  476 
 477 
Antimicrobial susceptibility testing of Danish clinical isolates  478 
Antimicrobial susceptibility testing was performed on a selection of clinical isolates 479 
obtained from the Danish surveillance of MRSA and S. aureus causing bacteraemia.  480 
The selection was based on a total of 270 isolates including 100 isolates (52 MSSA, 481 
48 MRSA) from 2011 on which whole genome sequence data were previously 482 
obtained and 170 consecutively received non-CC398 MRSA isolates in 2016. spa 483 
types were obtained for all isolates. Antimicrobial susceptibility testing was performed 484 
as described above except that 0.5 McFarland inoculum was prepared using a 485 
densitometer and ISA plates with and without 15 µg/ml clavulanic acid was 486 
purchased as custom made plates (SSI Diagnostica, Hilleroed, Denmark).  487 
 488 
Expression and purification of PBP2a variants in E. coli 489 
PBP2A variants (PBP2aE246, PBP2aE246G and PBP2aM122I from MRSA strains RVC5, 490 
BCVA289 and ARARH150, respectively; residues 26-668, with a G26M mutation) 491 
were overexpressed using the auto-induction expression method at 25ºC 55. Cells 492 
were harvested by centrifugation after 20 hours of expression and lysed using 493 
Bugbuster (Novagen, Merck Millipore) containing 10 U/ml of benzonase nuclease 494 
(Novagen, Merck Millipore) and Protease Inhibitor Tablets, EDTA-free (Pierce 495 
Biotechnology, Thermo Fisher Scientific), following the manufacturer’s instructions. 496 
After cell disruption, the lysates were cleared, and the soluble proteins were purified 497 
using HisPur Ni-NTA Resin columns (Pierce Biotechnology, Thermo Fisher Scientific) 498 
under native conditions, according to the manufacturer’s instructions. The expression 499 
and purification yields were monitored by SDS-PAGE. The most concentrated elution 500 
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fractions were buffer exchanged to 20 mM sodium phosphate buffer pH 7.4 using 501 
PD-10 Desalting Columns (GE Healthcare Life Sciences), following the 502 
manufacturer’s instructions. Protein concentrations were assessed using the BCA 503 
Protein Assay Kit (Pierce Biotechnology, Thermo Fisher Scientific). 504 
 505 
Bocillin FL PBP2a and penicillin G/clavulanic acid binding assays 506 
The binding affinity of PBP2a for different antibiotics has been determined using a 507 
fluorescent penicillin reporter reagent, Bocillin FL 56-58. In this study, the affinities of 508 
PBP2A variants for penicillin and clavulanic acid were determined using the same 509 
approach. Briefly, a reaction mixture containing 25 μg/ml of a purified PBP2a variant 510 
in 20 mM sodium phosphate buffer (pH 7.4) and various concentrations (0, 0.5, 1, 5, 511 
10, 20, 50, 100, 200, 500, 1000, 2000 μg/ml) of penicillin G or clavulanic acid was 512 
incubated at 37°C for 20 min. To test if the presence of clavulanic acid affected the 513 
affinity for penicillin G, increasing concentrations of penicillin G together with 15 514 
μg/ml of clavulanic acid were assayed. A final concentration of 20 μM Bocillin FL 515 
(13.3 μg/ml) was added to the reaction followed by 10 min incubation at 37°C. The 516 
reactions were quenched by adding SDS loading buffer and heating at 95°C for 10 517 
min. Samples were visualized using 10% Tris-Glycine-SDS PAGE. Protein gels were 518 
washed in distilled water for 10 min and scanned using a 473 nm laser of a Fuji 519 
Fluorescent Analyzer TLA-5100. Fluorescent intensity was quantified by ImageJ 520 
software and IC50 was calculated from three independent assays using GraphPad 521 
Prism 5 software. 522 
 523 
RNA isolation and quantitative real-time PCR (RT-qPCR) 524 
For each selected isolate, 15 ml of early log phase culture with an OD595nm of 0.3 was 525 
treated with 10 μg/ml oxacillin for 1 h at 37 °C to induce mecA expression and its 526 
respective untreated culture was used as a baseline control. After the induction, the 527 
OD595nm of the control culture was adjusted to be equal to that of the oxacillin induced 528 
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one if necessary and 10 ml of both cultures were spun for 10 min at 4,500 x g at 20 529 
°C. About 0.5 ml supernatant was left behind to re-suspend the pellet and 1 ml of 530 
RNAprotect Bacteria Reagent (Qiagen) was added and mixed immediately by 531 
vortexing. After incubation for 5 min at room temperature, cultures were spun for 5 532 
min at 10,000 x g at 4 °C to pellet the cells. Pellets were snap-frozen and stored at -533 
80 °C until RNA isolation. Total RNA was isolated using Qiagen RNeasy Mini Kit 534 
(Qiagen) and an additional DNAse treatment was performed with the Ambion 535 
TURBO DNA-free kit and cDNA was produced using QuantiTect Reverse 536 
Transcription Kit (Qiagen). RT-qPCR was performed using the SensiFast SYBR No-537 
ROX Kit (Bioline) on a Rotor-Gene Q machine (Qiagen) using mecA and blaZ 538 
primers Gene expression fold-changes in induced cultures were calculated relative to 539 
control cultures using the ∆∆Ct method 59 with gyrB as the reference. 540 
 541 
Wax moth larva infection and treatment 542 
The wax moth larvae assay was based on that previously described by Desbois et al 543 
60. Galleria mellonella larvae were purchased in bulk from Livefood UK. Larvae were 544 
stored at 4°C upon arrival and kept at 37°C during the course of the assay. MRSA 545 
strains RVC5, 0081, EC139, BCVA289 were selected for evaluation of antimicrobial 546 
activities of penicillin and clavulanic acid in combination. Single bacterial colonies 547 
were picked to inoculate 5 ml of TSB, and cultures were grown overnight (~16 hours) 548 
at 37°C and 200 rpm shaking. Cultures were then diluted 1:100 into 5 ml of fresh 549 
TSB and grown for a further 4 hours at 37°C and 200 rpm shaking. Cultures were 550 
then centrifuged at 2,500g for 10 minutes, and pellets resuspended in sterile 551 
phosphate buffered saline (PBS) to an OD595 of 0.2, giving approximately 1.5 × 108 552 
CFU/ml. For each strain, six groups of G. mellonella (n=10 in each group) were 553 
injected with 10 µl aliquots (~1.5 × 106 CFU) of resuspended culture behind the rear 554 
thoracic segments using a Tridak Stepper Pipette Dispenser (Dymax, UK). Groups of 555 
G. mellonella were treated by injection with 50 mg/kg vancomycin, 20 mg/kg penicillin 556 
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sodium salt, 20 mg/kg clavulanic acid, 20 mg/kg penicillin sodium salt combined with 557 
20 mg/kg clavulanic acid, 20 mg/kg amoxicillin, 20 mg/kg amoxicillin combined with 558 
20 mg/kg clavulanic acid or PBS at 2, 24 and 48 hours after inoculation. The 559 
treatments were given blind and the treatment identities not revealed until the 560 
experiment was completed. Larvae were considered dead when they did not respond 561 
to touch to the head. Survival curves were generated and analysed using GraphPad 562 
Prism 6 software. Fig. 5 shows results of a single representative experiment, a 563 
replication experiment with broadly similar results is shown in Supplementary Fig. 5.  564 
 565 
Murine infection model 566 
Fresh overnight colonies from a 5% horse blood agar plate were suspended in saline 567 
to an OD546 of 0.13, giving approximately 2 × 108 CFU/ml. Mice (NMRI female mice, 568 
26 - 30 gram (Taconic, Denmark), 6-8 weeks old were inoculated intramuscularly 569 
with 0.05 ml of the suspension in the left thigh (1 x 107 CFU). Approximately 0.5 hrs 570 
before inoculation, mice were treated orally with 45 µl Nurofen Junior (20 mg 571 
ibuprofen/ml - corresponding to 30 mg/kg) for pain relief. Four mice in each group 572 
were treated with a single subcutaneous dose of 0.2 ml with 10, 30 or 100 mg/kg 573 
amoxicillin (Amoxil, GlaxoSmithKline Middlesex UK) alone or in combination with 2, 6 574 
or 20 mg/kg clavulanic acid (Augmentin, Beecham Group Ltd, Middlesex, UK) or 40 575 
mg/kg vancomycin (Fresenius Kabi, Halden, Norway) or saline one-hour post 576 
infection. Mice were sacrificed at 1 hour for the start of treatment control group and at 577 
5 hours post infection for the treatment groups by cervical dislocation and thighs 578 
were collected and kept at -80ºC. Each sample thigh was homogenized in 5 ml saline 579 
using a Dispomix® Drive, and serially diluted in saline and twenty microliter spots of 580 
serial dilutions were plated on blood agar plates. All agar plates were incubated for 581 
18 - 24 hrs at 35°C. Statistical comparison was carried out using a 1 way ANNOVA 582 
and Dunnett´s multiple comparison, was performed for treatment groups comparing 583 
against the vehicle group in GraphPad Prism software. All animal procedures were 584 
 22
carried out at the Statens Serum Institute (SSI) and approved by the Danish Animal 585 
Procedure Inspectorate. Ethical approval was granted for the murine thigh infection 586 
model (2016-15-0201-01049). The SSI Animal Welfare Committee (SSI-AWC – 587 
equivalent an Institutional Animal Care and Use Committee (IACUC) requires that 588 
each experiment is further approved by the supervising laboratory animal 589 
veterinarians who are also part of the IACUC. All animals were randomised on arrival 590 
at SSI, and sample sizes were based on a combination of statistical analysis and the 591 
principles of 3R, that the minimum number of animals were used that were expected 592 
to provide statistically significant difference considering the expected intra-group 593 
variability of the infection model used. 594 
 595 
Growth curves  596 
To assess the effect of different mecA variants on the growth of MRSA strains in 597 
liquid culture, Bioscreen C optical growth analyzer (Lab system, Finland) was used to 598 
monitor the growth rates of deletion mutants A75∆mecA, BCVA289∆mecA and 599 
EC139∆mecA complemented with the three mecA variants. Briefly, overnight 600 
cultures were diluted 1/1000 into fresh SSM9PR minimal medium with or without 16 601 
μg/ml penicillin supplemented with 200 ng/ml Atc to induce the expression of 602 
plasmid-borne mecA gene. For each strain, 300 μl of inoculated medium was added 603 
into wells of the microplate in triplicate. Fresh medium with Atc was also added to 604 
three wells acting as blank controls. Cultures were incubated at 37 °C with 605 
continuous shaking for 24 hours and an optical density measurement at OD600nm was 606 
taken every 30 mins. Growth curves were analysed using the GraphPad Prism 6 607 
software and doubling time calculated using non-linear regression using an 608 
exponential growth equation with a least square fit, with Y0 constrained at the 609 
minimum optical density measured (an OD600nm of 0.069). 610 
 611 
Toxicity and biofilm assays  612 
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Immortalised human monocyte macrophage THP-1 cell lines were used as described 613 
previously61.  Briefly, the cell line was grown in individual 30 mL suspensions of 614 
RPMI-1640, supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1 μM 615 
L-glutamine, 200 units/mL penicillin, and 0.1 mg/mL streptomycin at 37°C in a 616 
humidified incubator with 5% CO2. Cells were routinely viewed microscopically every 617 
48–60 h and harvested by centrifugation at 1,000 rpm for 10 min at room 618 
temperature and resuspended to a final density of 1–1.2 x 106 cells/mL in tissue-619 
grade phosphate buffered saline. This procedure typically yielded >95% viability of 620 
cells as determined by trypan blue exclusion and easyCyte flow cytometry. To 621 
monitor S. aureus toxicity, 20 μL of cells were incubated with 20 μL of bacterial 622 
supernatant and incubated for 12 min at 37°C. For the USA300 strains, supernatants 623 
were diluted to 30% of the original volume in TSB as these isolates were 624 
considerably more toxic than the single-patient isolates. Cell death was quantified 625 
using easyCyte flow cytometry using the Guava viability stain according to 626 
manufacturer’s instructions. Experiments were done in triplicate, and error bars 627 
indicate the average ± the 95% confidence interval of multiple independent 628 
experiments.  629 
 630 
Biofilm formation was quantified using a 1:40 dilution from overnight cultures into 100 631 
µL of fresh TSB supplemented with 0.5% sterile filtered glucose (TSBG) in 96-well 632 
polystyrene plate (Costar). Perimeter wells of the 96-well plate were filled with sterile 633 
H2O and plates were placed in a separate plastic container inside a 37°C incubator 634 
and grown for 24 h under static conditions. For the transposon mutants, erythromycin 635 
(5 µg/mL) was added to the growth medium. Semi-quantitative measurements of 636 
biofilm formation on 96-well polystyrene plates were determined based on the 637 
method of Ziebuhr et al 23. Following 24-h growth, plates were washed vigorously five 638 
times in PBS, dried and stained with 150 μL of 1% crystal violet for 30 min at room 639 
temperature. Following five washes of PBS, wells were re-suspended in 200 μL of 640 
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7% acetic acid, and optical density at 595 nm was recorded using a Fluorimeter plate 641 
reader (BMG Labtech). For this experiment the assays were performed in triplicate 642 
on each plate and repeated three times. 643 
 644 
ECOFF determination  645 
In order to help split isolates into phenotypically “wildtype” and “non-wildtype” based 646 
on MIC distributions, a series of mixture models were fitted to the data for each drug 647 
independently, ranging from 1 to 5 normal distributions. Each model was fitted to the 648 
distribution of log-transformed MIC by maximum likelihood. The likelihood function 649 
was based on a multinomial distribution over the set of intervals 650 
[0,x1,...,xn,∞] where xi stands for each of the tested concentrations for the drug 651 
considered. For each drug, the 5 models were compared using Akaike’s Information 652 
Criterion to determine the optimal number k of normal distribution components. If the 653 
best model was k=1, the distribution was labelled as unimodal, and no further 654 
analysis was made. For drugs with k≥2, the following analyses were then carried out: 655 
1. Predicted distribution of MIC per component: for each component, we multiplied 656 
the probability mass at each concentration (= pdf integrated over the immediately 657 
lower interval) by the total number of isolates tested. 658 
2. Direct classification of isolates by component: for each MIC, we split the isolates 659 
into the k components according to their relative probabilities at that point. 660 
3. Optimal cut-off: we then sought to split each distribution into two modes. First, we 661 
estimated candidate cut-off points between each successive component of the 662 
mixture model. Each cut-off was computed as the concentration that minimised 663 
the risk of misclassification of isolates between the model components (achieved 664 
by minimising the difference between the cumulative density functions of the two 665 
components considered). For example, with k=3, there are three components 666 
centred at MIC values Y1<Y2<Y3; we then calculated two candidate cut-offs: one 667 
separating component 1 from 2+3, and the other separating 1+2 from 3. For each 668 
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cut-off, we then computed the number of isolates that would be misclassified, 669 
using the above direct classification as a reference: e.g. for the first cut-off, the 670 
number of isolates classified as 2 or 3 with MIC below the cut-off, plus the 671 
number of isolates classified as 1 with MIC above the cut-off. 672 
 673 
Bioinformatics  674 
Whole genome sequences were assembled using the pipeline described previously 675 
62. For each isolate the sequence reads were used to create multiple assemblies 676 
using VelvetOptimiser v2.2.5 63 and Velvet v1.2 64. The assemblies were improved by 677 
scaffolding the best N50 and contigs using SSPACE 65 and sequence gaps filled 678 
using GapFiller 66. Presence of PBP2a substitutions were identified by extracting the 679 
PBP2a sequence from the assembled genome sequences, aligning the PBP2a 680 
sequences using Muscle 67 in Seaview 68 and then identifying the presence of PBP2a 681 
substitutions using a custom python script. The mecA promoter mutations were 682 
identified using a similar approach using in silico PCR to identify the mecA promoter 683 
region and then aligning the mecA promoter sequence and identifying mecA 684 
mutations using a custom python script. The presence of the blaZ genes was 685 
confirmed using BLAST against assemblies, this identified that 273/298 of the 686 
previously screened WGS isolates had a single copy of blaZ (excluding blaZ-687 
negative or isolates with two copies or truncated copies of blaZ). BlaZ amino acid 688 
sequences were then extracted, aligned and amino acids at positions 128 and 216 689 
compared to identify the BlaZ type (Type A: 128:T, 216:S, Type B: 128:K, 216:N, 690 
Type C: 128:T, 216:N, Type D: 128:A, 216:S, Type E (LGA251): 128:L, 216:S, Type 691 
F (a distinct type identified in this work): 128:A, 216:N) as previously described 16,69,70. 692 
Phylogenetic analysis of the CC8 isolates was carried out as previously described 33, 693 
briefly, sequence reads were mapped using SMALT v0.7.4 694 
(http://www.sanger.ac.uk/science/tools/smalt-0) to the S. aureus USA300_FPR3757 695 
reference genome (accession: CP000255.1)71. A core genome alignment was 696 
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created after excluding mobile genetic element regions, variable sites associated with 697 
recombination (detected with Gubbins 72) and sites with more than 5% proportion of 698 
gaps (i.e. sites with an ambiguous base). A maximum likelihood (ML) phylogenetic 699 
tree was generated with RAxML v8.2.8 73 based on generalised time reversible 700 
(GTR) model with GAMMA method of correction for among site rate variation and the 701 
phylogenetic tree annotated using Figtree (http://tree.bio.ed.ac.uk/software/figtree/). 702 
Phylogenetic analysis of PBP2a sequences was constructed by using PhyML v3.0 in 703 
Seaview with a Whelan and Goldman (WAG) substitution model and 100 bootstrap 704 
replicates 74.  705 
 706 
 707 
Population analysis  708 
Population analysis was carried out as described by Kim et al 75  with minor 709 
modifications. Strains were grown overnight in tryptic-soya broth (TSB), and serial 710 
10-fold dilutions were plated in triplicate onto Iso-Sensitest Agar (Oxoid) plates 711 
containing varying concentrations of penicillin with 15 µg/ml clavulanic acid. Plates 712 
were incubated for 24 hours at 35°C. A mean of the three platings were plotted in 713 
Figure 5a. Biological replicates for strains BCVA289 and 0081 were generated and 714 
plotted in comparison to the original results in Supplementary Figure 4, showing 715 
broadly similar results.   716 
 717 
Structural modelling of PBP2a  718 
Co-ordinates from representative structures of both the Gly246 (accession code 719 
3ZFZ, 21) and Glu246 (accession code 1VQQ, 76) forms of PBP2a were used to 720 
compare possible effects induced by sidechain alteration. Figures were prepared 721 
using Chimera 77 and Pymol (The PyMOL Molecular Graphics System, Version 722 
1.2r3pre, Schrödinger, LLC).  723 
 724 
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Figure Legends 1046 
Figure 1: Penicillin susceptibility in the presence of clavulanic acid. (a) Figure 1047 
shows a representative image of two MRSA isolates grown on Iso-sensitest agar or 1048 
Iso-sensitest agar with 15μg/ml of clavulanic acid with a penicillin E-test strip applied, 1049 
the upper susceptible isolate shows increased susceptibility to penicillin in the 1050 
presence of clavulanic acid, while the lower resistant isolate shows only a minor 1051 
effect. (b) E-test determination of minimum inhibitory concentration of penicillin alone 1052 
(black) and penicillin plus 15 μg/ml clavulanic acid (grey) of a selection of penicillin-1053 
clavulanic acid susceptible (n=14) and resistant (n=10) MRSA isolates. The red line 1054 
indicates the current EUCAST clinical break point of ≤0.125 µg/ml. The effect of 1055 
clavulanic acid on susceptibility as measured by disk diffusion to different β-lactam 1056 
antibiotics in a panel of (c) penicillin-clavulanic acid resistant MRSA isolates (n=46), 1057 
and (d) penicillin-clavulanic acid susceptible MRSA isolates (n=32). Red bars 1058 
indicate isolates grown on Iso-Sensitest Agar (ISA) alone and blue bars indicate 1059 
isolates grown on ISA supplemented with 15μg/ml clavulanic acid. Y-axis indicates 1060 
the zone of inhibition in millimetres. Error bars indicate the standard deviation of the 1061 
mean. Note: OX(MHA) = Oxacillin performed on Müller-Hinton agar (recommended 1062 
media by EUCAST and CLSI). 1063 
 1064 
Figure 2: PBP2a substitutions mediating pencillin susceptibility. (a) Minimium 1065 
inhibitory concentrations (MIC) of penicillin (black) or penicillin in the presence of 15 1066 
µg/ml clavulanic acid (grey) for wildype strains EC139 (ST398) and BCVA289 1067 
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(USA300), and mecA mutants and complemented mutant strains with either an 1068 
empty vector (p) or one of the three different alleles of mecA (PBP2a246E (p246E), 1069 
PBP2a246G (p246G), and PBP2a112I (p112I). Results presented are the mean of three 1070 
independent experiments. (b) Bocillin competition assay to determine the IC50 of 1071 
penicillin for the three PBP2a variants (PBP2a246E – ‘WT’, PBP2a246G and 1072 
PBP2aM122I). (c) Bocillin competition assay to determine the IC50 of penicillin in the 1073 
presence of 15µg/ml clavulanic acid for the three PBP2a variants (PBP2a246E – ‘WT’, 1074 
PBP2a246G and PBP2aM122I). The fluorescence intensity of the bands was plotted as 1075 
the percentage of unbound proteins as a function of penicillin G concentration, and 1076 
the IC50 value was calculated from the plot. Data points represent the average of 1077 
three replicates and the curve is the predicted nonlinear regression result. (d) Mixture 1078 
models of MIC distributions of 298 MRSA isolates for penicillin in the presence of 15 1079 
µg/ml clavulanic acid, the best model is a mixture of 4 normal distributions, with a 1080 
proposed cut-off at 2.449, and (e) for penicllin alone, the best model is a mixture of 4 1081 
normal distributions, with a proposed cut-off at 0.218. The graphs show the proposed 1082 
categorisation of the MIC distribution into “wildtype” isolates (low MIC, green hues) 1083 
and “non-wildtype” isolates (high MIC, amber hues), and the proposed empirical cut-1084 
off as the vertical dashed line. Amber isolates that fall below the cut-off and green 1085 
isolates that fall above the cut-off show the expected classification errors by applying 1086 
the cut-off. 1087 
 1088 
Figure 3: Genetic basis of MRSA penicillin/clavulanic acid susceptibility. (a) 1089 
Summary of PBP2a substitutions and mecA promoter mutations. Figure shows a 1090 
representation of the domain structure of the PBP2a protein and mecA promoter with 1091 
the location of the two PBP2a substitutions and mecA promoter associated with 1092 
penicillin susceptibility indicated and mean penicillin MIC in the presence of 15 µg/ml 1093 
of clavulanic acid for isolates with that genotype. (b) Relative mecA expression 1094 
measured by RT-qPCR. Figure shows the relative mecA expression after oxacillin 1095 
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induction, normalised to gyrB for isolates with mecA[-7]:T (n=3), mecA[-7]:G (n=7) 1096 
and mecA[-33]:T (n=6). Error bars indicate the standard deviation of the mean. Data 1097 
were analysed with a two-tailed, unpaired t-test. * P = 0.0048, ** P = 0.0016. (c) MIC 1098 
distributions for penicillin (upper graph) and penicillin with 15 µg/ml clavulanic acid 1099 
(lower graph) with the number of isolates with each genotype combination of PBP2a 1100 
substitutions and mecA promoter mutations - indicated by colouring of the histogram 1101 
bars. (d) Joint distribution of MIC for 298 MRSA isolates, x axis shows penicillin MIC 1102 
and y axis shows pencillin MIC in the presence of 15 µg/ml clavulanic acid. Colour 1103 
and shape of the plot points indicate the genotype of the isolate.  1104 
 1105 
Figure 4: Prevalence and population genomics of penicillin-clavulanic acid.  1106 
(a) Graph shows the percentage abundance in the overall population and by clonal 1107 
complex (CC) of penicillin-clavulanic acid susceptible and resistant genotypes in 1108 
2282 clinical MRSA isolates from Cambridge, UK (b) Presence of SCCmec elements 1109 
in clonal complex (CC)8 and USA300 isolates. Figure shows a maximum likelihood 1110 
phylogenetic tree constructed from core genome SNPs of 580 CC8 isolates. USA300 1111 
isolates are indicated by blue colouring of the branches. Tips of the tree indicate the 1112 
SCCmec type (red = IVa, blue = IVb = orange = IVc, pink = IVd, purple = IVg, NT 1113 
(light blue) = non-typeable, - = negative for SCCmec). Isolates that were 1114 
phenotypically tested for penicillin-clavulanic acid susceptibility are indicated with an 1115 
asterix. Additionally, isolates: BCVA289, which was used for in vivo testing (wax 1116 
moth) and 43484, which was used for in vivo testing (murine thigh) are included for 1117 
comparison. 1118 
 1119 
Figure 5: Penicillins and clavulanic acid are efficacious for the treatment of 1120 
susceptible MRSA. (a) Population analysis of resistance to penicillin and clavulanic 1121 
acid. Figure shows the log10 CFU/ml of the different strains at various concentrations 1122 
of penicillin G (µg/ml) in the presence of 15 µg/ml clavulanic acid on Isosenstest 1123 
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plates. Plotted points are the mean of three technical replicates (biological replicates 1124 
for BCVA289 and 0081 shown in Supplementary Fig. 4). Survival curves for wax 1125 
moth larvae (Galleria mellonella) infected with ~1.5 × 106 CFU of: (b) 0081 (ST22) 1126 
(penicillin-clavulanic acid MIC = 4 µg/ml - resistant), (c) RVC5 (ST22) (MIC = 12 1127 
µg/ml - resistant), (d) BCVA289 (ST8 - USA300) (MIC = 0.25 µg/ml - susceptible), 1128 
and (e) (EC139 (ST398) (MIC = 0.25µg/ml - susceptible). Ten larvae in each group 1129 
were experimentally infected and then treated at 2, 24, and 48 hours with 1130 
vancomycin (50 mg/kg), penicillin (20 mg/kg) clavulanic acid (20 mg/kg), penicillin-1131 
clavulanic acid (1:1 ratio - 20 mg/kg), amoxicillin (20 mg/kg), amoxicillin-clavulanic 1132 
acid (1:1 ratio - 20 mg/kg) and PBS alone. Presented data are from a single 1133 
representative experiment, a replication experiment is presented in Supplementary 1134 
Fig. 5. (f) Effect of amoxicillin alone and in combination with clavulanic acid against 1135 
MRSA in a murine thigh infection model. Four mice in each treatment group were 1136 
inoculated with 7 log10 CFU of MRSA strain 43484 (USA300) and treated 1-hour post 1137 
inoculation with a single subcutaneous injection of either vancomycin (40mg/kg), 1138 
Amoxicillin (Amox) (10, 30, 100 mg/kg) alone or in combination (5:1 ratio) with 1139 
clavulanic acid (Clav) (2, 6, 20 mg/kg).  The bar indicates the mean. **** indicates a 1140 
significant difference (p<0.0001, Dunnett's multiple comparisons test) between 1141 
vehicle control. NS indicates there was no significant difference (p=0.0982, Dunnett's 1142 
multiple comparisons test) between the combined amoxicillin 100 mg/kg: clavulanic 1143 
acid 20mg/kg and vancomycin 40 mg/kg.  1144 
 1145 
Figure 6: PBP2a246G substitution provides an increased growth rate in the 1146 
presence of penicillin. Figure shows growth curves for strain BCV289∆mecA grown 1147 
in (a) SSM9PR minimal medium and (b) SSM9PR with 16 μg/ml penicillin, strain 1148 
EC139∆mecA grown in (c) SSM9PR minimal medium and (d) SSM9PR with 16 1149 
μg/ml penicillin, and strain A75∆mecA grown in (e) SSM9PR minimal medium and (f) 1150 
SSM9PR with 8 μg/ml penicillin. Lines are coloured depending on the vector the two 1151 
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strains were complemented with: orange = vector only control, green = vector 1152 
expressing mecA246G, blue = vector expressing mecA246E, black = vector expressing 1153 
mecA122I. The mean of a minimum of 6 independent replicates are plotted and error 1154 
bars indicate standard deviation.  1155 
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0 4 8 12 16 20 240.060.120.240.480.96 HoursLog2 OD600 0 4 8 12 16 20 240.060.120.240.480.96 ΔmecA+pΔmecA+p246GΔmecA+p246EΔmecA+p122I0 4 8 12 16 20 240.060.120.240.480.96 0 4 8 12 16 20 240.060.120.240.480.96BCVA289 (ST8-USA300) EC139 (ST398)0 4 8 12 16 20 240.060.120.240.480.96 Hours0 4 8 12 16 20 240.060.120.240.480.96 Hours A75 (ST22)a bc de f
